Evolus Stock Price, News & Analysis

Evolus, Inc. (NASDAQ: EOLS) has announced that its submission for regulatory approval of Nuceiva® (prabotulinumtoxinA) has been accepted by the Australian Therapeutics Good Administration (TGA). This is a significant milestone for the company's international growth strategy, as Australia represents one of the largest global markets for aesthetics. Nuceiva® is already approved in the U.S. as Jeuveau®, and in Europe and Canada. Evolus aims to complete the TGA approval process in 2023 and plans to launch Nuceiva® in select European countries later this year.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, announced participation in the Virtual 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, from 4:20 PM to 4:50 PM ET. The event will showcase Evolus' focus on delivering breakthrough products, including its FDA-approved neurotoxin, Jeuveau^®. Interested parties can access an audio webcast on the investor relations section of Evolus’ website, with a replay available for 90 days.

Evolus, Inc. (NASDAQ: EOLS) reported preliminary unaudited net revenues of approximately $34.7 million for Q4 2021, marking a 68% increase from the previous year. For full-year 2021, total net revenues reached approximately $99.7 million, a 76% growth over 2020. The company expects 2022 revenues between $143 million and $150 million, anticipating growth of 43% to 50%. As of December 31, 2021, Evolus maintains a strong cash position of $146.3 million. The company plans to enhance market presence and launch new products in 2022.

Evolus, Inc. (NASDAQ: EOLS) has appointed Brady Stewart, a digital and beauty innovator, to its Board of Directors, enhancing its leadership team. Stewart brings over 20 years of experience in digital innovation and direct-to-consumer strategies, currently serving as Chief Commercial Officer at Forma Brands. The Chairman, Vikram Malik, emphasized her potential contribution as the company aims to be a leading multi-product aesthetics company. Stewart expressed her excitement to join at a pivotal moment, highlighting the potential of the company's product, Jeuveau®, in transforming the aesthetic neurotoxin industry.

Tenaya Therapeutics (NASDAQ: TNYA) announced two key appointments: Karah Parschauer to its Board of Directors and Joanna Auch as Senior VP of People and Culture. These appointments aim to strengthen Tenaya's leadership amid its transition to a public company with over 100 employees. CEO Faraz Ali highlighted that both individuals bring valuable experience and will enhance the company's capabilities in drug development for heart disease. Parschauer has extensive biopharmaceutical experience and previously held roles at Ultragenyx, while Auch has over 15 years in HR.

Evolus, Inc. (NASDAQ: EOLS) has been added to the Nasdaq Biotechnology Index (NBI) as part of its annual reconstitution. This inclusion is expected to enhance Evolus' visibility and shareholder base. CFO Lauren Silvernail indicated that robust sales and market share gains position the company for a strong finish in 2021 and growth in 2022. Evolus focuses on innovative aesthetic products, particularly Jeuveau®, a neurotoxin exclusively for aesthetics, approved in 2019 by the FDA.

Evolus, Inc. (NASDAQ: EOLS) has secured a $125 million term loan financing with Pharmakon Advisors, L.P. This facility includes an initial draw of $75 million to support corporate purposes and achieve cash flow breakeven. A second $50 million draw is available before December 31, 2022, providing potential for strategic transactions. The loan matures in six years with interest-only payments for the first 39 months. The CEO emphasizes this funding strengthens their capital structure and supports growth in the aesthetic neurotoxin market.

Evolus, Inc. (NASDAQ: EOLS) announced the participation of its management team in two investment conferences this November. The first event is the Stifel 2021 Virtual Healthcare Conference on November 16 at 2:40 pm ET. The second is the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30 at 7:30 am ET. Audio webcasts of both events will be available on Evolus' investor relations website for 90 days following the presentations. Evolus specializes in aesthetic products, including Jeuveau®, the first neurotoxin solely for aesthetics.

Evolus, Inc. reported a record third quarter ending September 30, 2021, with U.S. net revenues reaching $26.7 million, a 58% increase year-over-year. The company's cash position at quarter-end totaled $107.8 million. Key growth drivers included an increase in Jeuveau® customer accounts, rising to over 6,500, and a significant marketing push with over 850 unique campaigns, generating 395 million media impressions. The company also initiated a Phase II clinical program for an “extra strength” Jeuveau® dose aimed at extending duration.